Companies in #Diabetic Macular Edema

IRIDEX Corporation is an ophthalmic medical-device company that develops, manufactures and markets laser-based systems, delivery devices and consumable procedure probes for the treatment of glaucoma and retinal diseases. Founded in 1989 and long headquartered in Mountain View, California, the company's intellectual property centers on its proprietary MicroPulse technology, a tissue-sparing, sub-threshold laser approach that delivers laser energy in short pulses with cooling intervals, alongside the Cyclo G6 glaucoma laser platform, the MicroPulse P3 delivery device and the G-Probe family of transscleral probes. The company completed the relocation of its manufacturing operations from Mountain View to San Jose, California in October 2026 as part of a cost-reduction programme.

Kodiak Sciences is a precommercial, retina-focused biotechnology company based in Palo Alto, California, built around its Antibody Biopolymer Conjugate (ABC) platform, which conjugates a humanised anti-VEGF antibody to a high-molecular-weight phosphorylcholine-based biopolymer through a single-site covalent linkage to extend durability of effect in the eye. Its lead medicine, Zenkuda (tarcocimab tedromer), reported positive topline results in the pivotal Phase 3 DAYBREAK study in wet age-related macular degeneration on September 28, 2026, meeting its primary endpoint at a p-value of 0.0007 with non-inferior vision gains versus aflibercept at year one and 54% of patients on six-month dosing durability, and now has a BLA-ready profile across five positive Phase 3 studies. The company plans a multi-indication Biologics License Application in the fourth quarter of 2026 spanning wet AMD, diabetic retinopathy and retinal vein occlusion, while its bispecific VEGF/IL-6 inhibitor tabirafusp alfa tedromer (KSI-501) is being evaluated in wet AMD and diabetic macular edema.

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.

Surrozen is a clinical-stage biotechnology company developing targeted antibodies that selectively modulate Wnt signalling, the pathway that governs stem-cell renewal, tissue structure and repair, with its current focus on sight-threatening ophthalmic disease. Its lead candidate, SZN-8141, is a bifunctional antibody that combines Frizzled 4 (FZD4)-mediated Wnt agonism with VEGF antagonism to address both vascular leakage and retinal vascular integrity; the company submitted an Investigational New Drug application for SZN-8141 in diabetic macular edema in September 2026 and expects to begin the DUET Phase 1b/2a study by year-end 2026, with initial data anticipated in the second half of 2027. The earlier SZN-043 programme, built on the company's SWEETS technology, is a Wnt agonist antibody developed for severe liver disease, initially severe alcohol-associated hepatitis, and has completed a Phase 1a study in chronic liver disease and healthy volunteers ahead of a Phase 1b multiple-ascending-dose trial.